RT Journal Article
T1 Can resistance to aspirin be reversed after an additional dose?
A1 Vivas Balcones, Luis David
A1 Bernardo, Esther
A1 García Rubira, Juan Carlos
A1 Azcona, Luis
A1 Núñez Gil, Ivan
A1 González Ferrer, Juan José
A1 Macaya Miguel, Carlos
A1 Angiolillo, Dominick J.
A1 Fernández Ortiz, Antonio Ignacio
AB Aspirin resistance or aspirin non-responsiveness is a recently described phenomenon which has been consistently associated with an increased risk of cardiovascular events. This study was designed to determine the effects of an additional dose of 100 mg of aspirin on platelet function and proportion of aspirin non-responders using the platelet function analyzer-100 (PFA-100), in a well characterized population of stable coronary heart disease patients already on long-term aspirin treatment. Platelet function was assessed using PFA-100 in 141 patients (64.8 ± 10.1 years, 87.9% men) on long-term aspirin treatment (100 mg/day) before and 1 h after “in site” oral aspirin administration (100 mg). Prevalence of aspirin non-responders using PFA-100 was 50.7% (95% confidence interval 42.4–59). One hour after 100 mg of oral aspirin, reassessment of aspirin effects showed a prevalence of non-responders using PFA of 35.0% (95% CI 27.3–43.2) (P < 0.001 vs. pre-dose proportion). Using the PFA-100 system, reassessment of platelet function following oral administration of daily aspirin dosage significantly reduces the number of stable coronary disease patients considered to be non-responders to such treatment.
PB Springer
SN 0929-5305
YR 2011
FD 2011-10-01
LK https://hdl.handle.net/20.500.14352/99946
UL https://hdl.handle.net/20.500.14352/99946
LA eng
NO Vivas D, Bernardo E, García-Rubira JC, Azcona L, Núñez-Gil I, González-Ferrer JJ, et al. Can resistance to aspirin be reversed after an additional dose? J Thromb Thrombolysis. 2011;32:356-61
NO Estudio observacional donde se evaluó en 141 pacientes con enfermedad coronaria estable en tratamiento crónico con aspirina 100mg al día si una dosis adicional reduce el porcentaje de pacientes no respondedores al tratamiento antiagregante. Tras una dosis “extra” de aspirina 100mg, el número de pacientes no respondedores a la inhibición plaquetaria con aspirina se redujo un 15% (del 50,7 al 35%).
DS Docta Complutense
RD 21 jul 2024